/PYXS
PYXS Stock - Pyxis Oncology, Inc.
Healthcare|BiotechnologyNASDAQ
$1.27-26.30%
$0.46 (-26.30%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+423.1%upside
Target: $6.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PYXS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.26 – $1.29
TARGET (TP)$6.67
STOP LOSS$1.17
RISK/REWARD1:51.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.38
52W High$5.55
52W Low$0.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $16.15M | N/A | N/A | N/A | N/A |
| Gross Profit | $15.67M | N/A | N/A | N/A | $-444,000 |
| Gross Margin | 97.1% | N/A | N/A | N/A | N/A |
| Operating Income | $-89,460,000 | $-82,196,000 | $-123,481,000 | $-69,717,000 | $-12,894,000 |
| Net Income | $-77,331,000 | $-73,790,000 | $-120,717,000 | $-75,975,000 | $-12,828,000 |
| Net Margin | -478.9% | N/A | N/A | N/A | N/A |
| EPS | $-1.32 | $-1.85 | $-3.57 | $-2.53 | $-0.37 |
Company Overview
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 625.5% Upside
Now
$5
Low
$9
Average
$13
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | Stifel | Resumed | Buy | $9 |
| September 4th 2025 | Guggenheim | Initiation | Buy | $5 |
| November 21st 2024 | William Blair | Downgrade | Market Perform | - |
| November 8th 2024 | Stephens | Initiation | Overweight | $13 |
| August 8th 2024 | Stifel | Initiation | Buy | $10 |
| May 7th 2024 | Jefferies | Resumed | Buy | $10 |
| February 9th 2024 | BTIG Research | Initiation | Buy | $8 |
| January 23rd 2024 | Leerink Partners | Initiation | Outperform | $12 |
| September 5th 2023 | RBC Capital Mkts | Initiation | Outperform | $7 |
Earnings History & Surprises
PYXSBeat Rate
53%
Last 17 quarters
Avg Surprise
-118.1%
EPS vs Estimate
Beats / Misses
9/8
Last 12 quarters
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q1 24
+32.7%
$-0.33vs$-0.49
Q2 24
+77.8%
$-0.06vs$-0.27
Q3 24
+12.1%
$-0.29vs$-0.33
Q4 24
-9.4%
$-0.35vs$-0.32
Q1 25
+3.0%
$-0.32vs$-0.33
Q2 25
-20.7%
$-0.35vs$-0.29
Q3 25
+16.7%
$-0.30vs$-0.36
Q4 25
+2.8%
$-0.35vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.35 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.36 | $-0.35 | +2.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.29 | $-0.35 | -20.7% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $-0.33 | $-0.32 | +3.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.33 | $-0.29 | +12.1% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.27 | $-0.06 | +77.8% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.49 | $-0.33 | +32.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.57 | $-0.56 | +1.8% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-0.66 | $-0.41 | +37.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.84 | $-0.54 | +35.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.85 | $-1.04 | -22.4% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-0.76 | $-0.85 | -11.8% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.68 | $-0.79 | -16.2% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-0.62 | $-0.97 | -56.5% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.37 | $-1.98 | -435.1% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.51 | $-8.96 | -1656.9% | ✗ MISS |
Q4 2021 | Oct 8, 2021 | — | $-0.26 | — | — |
Latest News
RBC Capital Maintains Outperform on Pyxis Oncology, Lowers Price Target to $5
➖ NeutralBenzinga•Dec 19, 2025, 03:17 PM
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7
📈 PositiveBenzinga•Dec 19, 2025, 12:47 PM
Pyxis plummets following phase 1 data on candidate for head and neck cancer
📉 NegativeSeeking Alpha•Dec 18, 2025, 04:53 PM•Also:
Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.
➖ NeutralBenzinga•Dec 18, 2025, 02:16 PM
Pyxis Oncology Shares Early Phase 1 Data For MICVO Showing Meaningful Clinical Activity In Recurrent Or Metastatic Head And Neck Cancer
📈 PositiveBenzinga•Dec 18, 2025, 12:05 PM
Pyxis Oncology Files For Mixed Shelf Of Up To $350M And Also Files For $150M Stock Sale Agreement With Leerink Partners
➖ NeutralBenzinga•Nov 26, 2025, 02:01 PM
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8
📈 PositiveBenzinga•Nov 24, 2025, 02:04 PM
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7
📈 PositiveBenzinga•Nov 4, 2025, 03:37 PM
Pyxis Oncology shares are trading higher. The company reported Q3 financial results.
📈 PositiveBenzinga•Nov 3, 2025, 04:50 PM
Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate
📉 NegativeBenzinga•Nov 3, 2025, 12:09 PM
Pyxis Oncology To Present Translational Data For Micvotabart Pelidotin At Upcoming Medical Meetings; Findings Demonstrate MICVO's Effects On Tumor Microenvironment Remodeling And Immune Activation
📈 PositiveBenzinga•Oct 13, 2025, 08:09 PM
Guggenheim Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $5
📈 PositiveBenzinga•Sep 4, 2025, 01:54 PM
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
➖ NeutralBenzinga•Aug 19, 2025, 11:02 AM
Frequently Asked Questions about PYXS
What is PYXS's current stock price?
Pyxis Oncology, Inc. (PYXS) is currently trading at $1.27 per share. The stock has moved -26.30% today.
What is the analyst price target for PYXS?
The average analyst price target for PYXS is $6.67, based on 1 analyst.
What sector is Pyxis Oncology, Inc. in?
Pyxis Oncology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PYXS's market cap?
Pyxis Oncology, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does PYXS pay dividends?
No, Pyxis Oncology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to PYXS for comparison